
Invitae Corporation NVTA
Quarterly report 2023-Q3
added 11-08-2023
Invitae Corporation Long Term Debt Current 2011-2026 | NVTA
Annual Long Term Debt Current Invitae Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 14.6 M | 12.4 M | 8.79 M | 4.87 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 14.6 M | 4.87 M | 10.2 M |
Long Term Debt Current of other stocks in the Diagnostics research industry
| Issuer | Long Term Debt Current | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
2.18 M | - | -6.23 % | $ 30.6 M | ||
|
Akumin
AKU
|
17.2 M | - | -17.87 % | $ 25.9 M | ||
|
Bioventus
BVS
|
3.3 M | $ 8.94 | 0.73 % | $ 596 M | ||
|
Brainsway Ltd.
BWAY
|
824 K | $ 13.59 | -0.48 % | $ 99.4 M | ||
|
Castle Biosciences
CSTL
|
1.66 M | $ 25.77 | -0.25 % | $ 716 M | ||
|
Aspira Women's Health
AWH
|
77 K | - | -6.19 % | $ 10.5 M | ||
|
DexCom
DXCM
|
21.6 M | $ 67.71 | 2.07 % | $ 26.4 B | ||
|
Guardant Health
GH
|
27.7 M | $ 88.81 | 1.87 % | $ 11.1 B | ||
|
Charles River Laboratories International
CRL
|
57.7 M | $ 154.58 | 1.72 % | $ 7.66 B | ||
|
CareDx, Inc
CDNA
|
6.52 M | $ 17.48 | 0.92 % | $ 931 M | ||
|
Accelerate Diagnostics
AXDX
|
829 K | - | -61.36 % | $ 2.46 M | ||
|
Exact Sciences Corporation
EXAS
|
33.6 M | $ 103.94 | 0.09 % | $ 19.6 B | ||
|
IQVIA Holdings
IQV
|
93 M | $ 168.75 | 2.34 % | $ 29 B | ||
|
Global Cord Blood Corporation
CO
|
147 K | - | - | $ 399 M | ||
|
Genetic Technologies Limited
GENE
|
264 K | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
21.5 M | - | 0.12 % | $ 80.1 M | ||
|
Fulgent Genetics
FLGT
|
1.44 M | $ 15.39 | 2.94 % | $ 465 M | ||
|
Biodesix
BDSX
|
719 K | $ 16.36 | -5.38 % | $ 2.12 B | ||
|
ICON Public Limited Company
ICLR
|
24.3 M | $ 99.64 | 2.08 % | $ 8.22 B | ||
|
Anixa Biosciences
ANIX
|
41 K | $ 2.9 | 2.11 % | $ 94.1 K | ||
|
Danaher Corporation
DHR
|
199 M | $ 195.42 | 2.11 % | $ 139 B | ||
|
Biocept
BIOC
|
518 K | - | -13.05 % | $ 7.29 M | ||
|
Heska Corporation
HSKA
|
2.94 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
475 K | - | -20.0 % | $ 1.06 M | ||
|
Pacific Biosciences of California
PACB
|
448 K | $ 1.42 | 4.04 % | $ 426 M | ||
|
Illumina
ILMN
|
79 M | $ 122.1 | 2.36 % | $ 19.4 B | ||
|
Quest Diagnostics Incorporated
DGX
|
174 M | $ 198.12 | -0.41 % | $ 22 B | ||
|
QIAGEN N.V.
QGEN
|
23.4 M | - | - | $ 10.6 B | ||
|
BioNano Genomics
BNGO
|
2.99 M | $ 1.11 | 0.04 % | $ 1.41 M | ||
|
DarioHealth Corp.
DRIO
|
111 K | $ 9.0 | 6.89 % | $ 255 M | ||
|
NeoGenomics
NEO
|
4.78 M | $ 8.26 | 0.24 % | $ 1.06 B | ||
|
Neogen Corporation
NEOG
|
5.64 M | $ 9.23 | 1.26 % | $ 2 B | ||
|
Lantheus Holdings
LNTH
|
3.8 M | $ 80.14 | 2.09 % | $ 5.41 B | ||
|
Chembio Diagnostics
CEMI
|
915 K | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
264 K | - | - | $ 9.42 M | ||
|
Co-Diagnostics
CODX
|
838 K | $ 4.4 | 101.83 % | $ 129 M | ||
|
Medpace Holdings
MEDP
|
23.2 M | $ 457.18 | 0.78 % | $ 13.2 B | ||
|
Motus GI Holdings
MOTS
|
169 K | - | -34.28 % | $ 263 K | ||
|
Mettler-Toledo International
MTD
|
35.1 M | $ 1 210.97 | 1.02 % | $ 25 B | ||
|
Celcuity
CELC
|
172 K | $ 114.41 | -0.42 % | $ 4.51 B | ||
|
DermTech
DMTK
|
3.07 M | - | -11.32 % | $ 2.94 M | ||
|
National Research Corporation
NRC
|
451 K | $ 17.74 | 1.95 % | $ 397 M | ||
|
Twist Bioscience Corporation
TWST
|
13.8 M | $ 47.21 | 4.89 % | $ 2.82 B | ||
|
Enzo Biochem
ENZ
|
841 K | - | -8.98 % | $ 14.8 K | ||
|
Natera
NTRA
|
7.64 M | $ 198.98 | 0.66 % | $ 19.6 B |